Market
Which therapy will lead the market share for sickle cell treatment by end of 2025?
2
Resolution / Starting Odds
BEAM-101 leads • 33%
Reni-cel leads • 33%
Casgevy leads • 33%
Market analysis reports from reputable financial or healthcare analysts
Story
Beam Therapeutics' BEAM-101 Shows Superior Results at ASH 2024, Stock Rises
Dec 9, 2024, 12:57 PM
Beam Therapeutics Inc. has reported promising clinical data for its sickle cell gene therapy, BEAM-101, at the American Society of Hematology (ASH) 2024 conference. The therapy has shown an average of 64-65% fetal hemoglobin (HbF) levels in patients, significantly higher than its competitors Reni-cel and Casgevy. BEAM-101's efficient manufacturing process allows for fewer mobilization cycles, with an average of 1.4 cycles, compared to Reni-cel's 4.6 and Casgevy's 4.7. This efficiency could potentially expand the eligible patient population for gene editing therapies. Additionally, Beam's approach includes a novel conditioning regimen using an anti-CD117 antibody, aiming to reduce toxicity and increase the feasibility of the treatment. The company's stock saw a 6.5% increase following the announcement, reflecting positive market sentiment towards the potential of BEAM-101.
View original story
Similar markets
Mutation-specific gene therapy • 33%
Universal gene therapy • 33%
No approval • 34%
Find new partner • 25%
Seek acquisition • 25%
Discontinue • 25%
Self-commercialize • 25%
LEQEMBI leads market • 25%
No clear market leader • 25%
Competitor drug leads market • 25%
Other • 25%
AstraZeneca • 25%
Johnson & Johnson • 25%
Other • 25%
Roche • 25%
Surgical Treatments • 25%
Other Pharmaceuticals • 25%
Zepbound • 25%
CPAP Machines • 25%
Approved in both • 25%
Approved in US • 25%
Not approved • 25%
Approved in EU • 25%
CPAP devices • 25%
Zepbound • 25%
Other treatments • 25%
Alternative medications • 25%
10-20% • 25%
Less than 10% • 25%
More than 30% • 25%
20-30% • 25%
Second • 25%
Third • 25%
Lower • 25%
Leading • 25%
Gene Editing • 25%
CAG Repeat Reduction • 25%
Neuroprotective Agents • 25%
Other • 25%
